AbCellera Biologics Inc
Research AbCellera Biologics Inc (ABCL) on Bullrun: market cap USD 3.83B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerABCL
- ExchangeNASDAQ
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 3.83B
- Financial periodQ2 2026
- RevenueUSD 4.05M
- Net income-USD 55.43M
- Free cash flowUSD 23.79M
Valuation Snapshot
latest market cap is USD 3.83B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 75.13M | -USD 146.41M | -USD 174.07M | n/a | -0.49 | USD 128.51M | USD 143.22M | USD 966.90M |
| FY2024 | USD 28.83M | -USD 162.86M | -USD 186.95M | n/a | -0.55 | USD 55.60M | USD 65.36M | USD 1.06B |
| FY2023 | USD 38.03M | -USD 146.40M | -USD 120.82M | 100.0% | -0.51 | USD 52.20M | USD 77.38M | USD 1.15B |
| FY2022 | USD 485.42M | USD 158.52M | USD 206.70M | n/a | 0.5 | USD 44.90M | USD 36.78M | USD 1.23B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 3.83B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.03B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 866.57M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.66B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 2.90B | 12.8 | n/a | n/a |
| 2021 | 2021-12-31 | USD 4.05B | 30.4 | n/a | n/a |
About AbCellera Biologics Inc
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is AbCellera Biologics Inc's market cap?
AbCellera Biologics Inc's market capitalization is USD 3.83B.
What does AbCellera Biologics Inc do?
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis.